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ABSTRACT 
[Introduction] 
Proteasome inhibitors (PI), mainly targeting the β5 subunit of the 20S proteasome, are 
widely used in the treatment of multiple myeloma (MM). However, PI resistance remains 
an unresolved problem in the therapy of relapsed and refractory MM. To develop a new 
PI that targets other proteasome subunits, we examined the anti-MM activity of a novel 
syringolin analog, syringolog-1, which inhibits the activity of both the β5 and β2 subunits.  
[Methods and Results] 
Syringolog-1 exhibited marked cytotoxicity against various MM cell lines and anti-tumor 
activity towards bortezomib (Btz)-resistant MM cells through the dual inhibition of 
chymotrypsin-like (β5 subunit) and trypsin-like (β2 subunit) activities. MM cells, 
including Btz-resistant cells, showed elevated CHOP and NOXA expression after 
syringolog-1 treatment, indicating the induction of excessive endoplasmic reticulum 
stress during syringolog-1 treatment. Similar activities of syringolog-1 were also 
observed in freshly prepared MM cells derived from patients. To clarify the anti-tumor 
mechanism of dual inhibition of both the β5 and β2 subunits of the proteasome, PSMB5 
and PSMB7 were co-inhibited in MM cells. This resulted in increased apoptosis of MM 
cells accompanied by accumulation of ubiquitinated proteins compared to inhibition of 
either PSMB7 or PSMB5 alone, indicating an enhanced effect by double inhibition of β2 
and β5 activities. 
[Discussion] 
In conclusion, this syringolin analog, a dual inhibitor of proteasome β2 and β5 activities, 
exhibited potent anti-tumor effects on MM cells and may be useful for overcoming Btz-
resistance in the treatment of MM. 
